Stina Mui Singel

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano et al. · New England Journal of Medicine · 2018 · 2.5K citations · Full text

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 463 citations · Full text

First-line Therapy, Breast Oncology, Medicine +7

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer

Mafalda Oliveira, Cristina Saura, Paolo Nucíforo et al. · Annals of Oncology · 2019 · 149 citations · Full text

Breast Oncology, Phase Ii Trial, Medicine +6

A Targeted RNAi Screen of the Breast Cancer Genome Identifies <i>KIF14</i> and <i>TLN1</i> as Genes That Modulate Docetaxel Chemosensitivity in Triple-Negative Breast Cancer

Stina Mui Singel, Crystal Cornelius, Kimberly Batten et al. · Clinical Cancer Research · 2013 · 128 citations · Full text

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

Peter Vuylsteke, Manon Huizing, Katarína Petráková et al. · Annals of Oncology · 2016 · 110 citations · Full text

Metastatic Breast Cancer, Breast Oncology, Phase Ii +9